Year All2024202320222021202020192018201720162015201420122011 Jul 26, 2023 Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023 Jul 20, 2023 Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference Jul 13, 2023 Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China Jun 29, 2023 Ardelyx, Inc. Reports Employment Inducement Grants Jun 5, 2023 Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase May 31, 2023 Ardelyx to Present at the Jefferies 2023 Healthcare Conference May 23, 2023 Ardelyx, Inc. Reports Employment Inducement Grants May 17, 2023 Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor) May 15, 2023 Ardelyx, Inc. Reports Employment Inducement Grants May 9, 2023 Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults